Palexia Retard

Active Ingredient:: Tapentadol Hydrochloride
Origin:: EU

Palexia Retard (Tapentadol Hydrochloride)

International sale not permitted. Listed for the domestic market and B2B only.

Tapentadol Hydrochloride, the active ingredient in Palexia Retard, is an opioid analgesic presented as a controlled‑release formulation for oral use. It is indicated for the management of moderate to severe chronic pain in adult patients when other analgesics are insufficient.
GNH India supplies Palexia Retard as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Manufacturer / TM Owner

Sa Grünenthal N.V.

Select Quantity

Pack/s

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

First Name

Last Name

Phone

Delivery Country

Delivery PostCode/Zipcode

Select Your Profile

I have read and agree to the terms & conditions, including the privacy policy, return policy, and usage terms as applicable to this request.

Indications & Clinical Uses

Palexia Retard is an opioid analgesic that acts within the central nervous system to relieve pain.

Chronic musculoskeletal pain: Provides sustained relief for conditions such as osteoarthritis and low‑back pain.
Neuropathic pain: Helps reduce pain associated with diabetic peripheral neuropathy.
Cancer‑related pain: Offers long‑acting analgesia for breakthrough pain in oncology patients.

How It Works

Tapentadol Hydrochloride exerts its analgesic effect through a dual mechanism: it is a µ‑opioid receptor agonist that activates central opioid pathways and simultaneously inhibits norepinephrine reuptake, enhancing descending inhibitory pain signals. This combined action reduces the perception of pain without relying solely on opioid receptor activation.

Side Effects

Tapentadol may cause a range of adverse reactions, most of which are dose‑dependent and reversible.

Common Side Effects

Nausea: mild to moderate stomach upset.
Constipation: reduced bowel movements.
Dizziness: sensation of light‑headedness.
Somnolence: increased sleepiness.
Headache: mild cranial discomfort.
Dry mouth: reduced salivation.

Serious or Rare Side Effects

Respiratory depression: slowed breathing that may be life‑threatening.
Seizures: rare convulsive episodes.
Severe hypotension: marked drop in blood pressure.
Allergic reactions: rash, itching, or anaphylaxis.
Dependence or abuse potential: risk of misuse with prolonged use.
Adrenal insufficiency: rare hormonal imbalance.

Precautions & Warnings

When prescribing Tapentadol, clinicians should evaluate patient history and monitor for safety concerns.

Assess renal function: adjust use in severe impairment.
Evaluate hepatic function: caution in liver disease.
Review concomitant CNS depressants: increased sedation risk.
Monitor for signs of abuse: implement risk‑mitigation strategies.
Pregnancy and lactation: use only if clearly needed.
Store below 25°C: keep in the original container, protect from moisture and light.

Avoid Interactions

Tapentadol interacts with several drug classes; careful review is essential.

Major Interactions (Avoid)

CNS depressants (e.g., benzodiazepines, barbiturates): may cause profound sedation and respiratory depression.
MAO‑inhibitors: risk of hypertensive crisis or serotonin syndrome.\n- Strong CYP2D6 inhibitors (e.g., fluoxetine): may increase tapentadol levels.

Moderate Interactions (Monitor Closely)

Serotonergic agents (e.g., SSRIs, SNRIs): potential for serotonin syndrome.
Antihistamines: additive sedation.
Diuretics: may enhance hypotensive effects.
Alcohol: increases central nervous system depression.

Frequently Asked Questions

Palexia Retard is a controlled‑release formulation of tapentadol hydrochloride that is prescribed for the management of moderate to severe chronic pain, including musculoskeletal, neuropathic and cancer‑related pain, when other analgesics are insufficient.

Tapentadol provides analgesia through a dual mechanism: it activates µ‑opioid receptors in the central nervous system and inhibits the reuptake of norepinephrine, which together enhance descending pain‑inhibitory pathways and lower the perception of pain.

The dose of Palexia Retard is individualized by the prescribing clinician based on the patient’s pain severity, prior opioid exposure, renal and hepatic function, and response to therapy. No fixed regimen is provided here.

Tapentadol is classified as a pregnancy‑category C medication; it should be used only if the potential benefit justifies the potential risk to the fetus. It is excreted in breast milk, so breastfeeding is not recommended unless the benefit to the infant outweighs the risk.

To place an order, submit an enquiry on the Palexia Retard product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any required import documentation.

Compared with traditional opioids such as morphine, tapentadol offers a dual mechanism that may provide effective analgesia with a potentially lower incidence of some opioid‑related side effects, such as constipation, due to its norepinephrine‑reuptake inhibition component.

Palexia Retard tablets should be stored below 25 °C (77 °F) in their original packaging, protected from moisture, heat and direct sunlight. Keep the container tightly closed and out of reach of children.

Published by

GNH India Pharmaceuticals Limited

Licensed pharmaceutical supplier

Last updated: 11 Oct 2026

Disclaimer

International sale not permitted. Listed for the domestic market and B2B only.

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.